Mono, caused by the Epstein-Barr virus (EBV), is strongly linked to several autoimmune diseases. The connection is strongest with multiple sclerosis, where a landmark 2022 study published in Science found that EBV infection increases the risk of developing MS by 32-fold. But the relationship extends beyond MS to lupus, rheumatoid arthritis, and other conditions. About 95% of adults worldwide carry latent EBV, yet only a small fraction develop autoimmune disease, which means genetics, timing, and other environmental factors all play a role in determining who is affected.
The Multiple Sclerosis Connection
The strongest evidence links EBV to multiple sclerosis. Researchers at Harvard tracked over 10 million U.S. military personnel over 20 years, comparing those who were infected with EBV to those who weren’t. People who became infected with the virus saw their MS risk jump 32-fold. Those who already had the virus at the start of the study had a 26-fold increased risk. Critically, infection with other viruses, including cytomegalovirus (which spreads in a similar way), did not raise MS risk at all. This specificity is what makes the EBV-MS link so compelling.
The time between mono and MS symptoms varies widely and depends heavily on when infection occurs. People who catch mono as young children may not develop MS for 25 to 28 years. But those infected as young adults, around age 25, may develop symptoms in as few as 7 to 8 years. This gap shrinks dramatically during puberty, particularly for women, who show a twofold increase in MS incidence compared to men during peak risk periods and a steeper drop in the delay between infection and disease onset.
How EBV Triggers the Immune System to Attack Itself
The primary mechanism behind EBV-related autoimmunity is molecular mimicry. Parts of the virus look structurally similar to proteins in your own body. When your immune system builds antibodies to fight EBV, some of those antibodies also latch onto your own tissues by mistake. In MS, this means immune cells trained to recognize viral proteins end up attacking the protective coating around nerve fibers in the brain and spinal cord.
EBV also disrupts the immune system more directly by hijacking B cells, the white blood cells responsible for producing antibodies. Normally, B cells that react against your own body are programmed to self-destruct. But EBV produces proteins that block this self-destruct process. One viral protein mimics a key survival signal for B cells, keeping them alive indefinitely. Another blocks the cell’s ability to detect damage and shut itself down. The result is that self-reactive B cells, which should have been eliminated, survive and continue producing antibodies that target healthy tissue.
The Link to Lupus
In systemic lupus erythematosus (SLE), the connection to EBV follows a specific chain of events. After infection, the immune system produces antibodies against a viral protein called EBNA-1. As the immune response matures and becomes more complex, some of those anti-EBNA-1 antibodies begin cross-reacting with the body’s own proteins, particularly components of cell nuclei. This cross-reactivity is the molecular mimicry step where an antiviral response quietly becomes an autoimmune one.
From there, the immune system undergoes what researchers call epitope spreading: once it starts reacting to one self-protein, the response cascades and begins targeting additional self-proteins. Research published in Frontiers in Immunology describes a progression from EBV infection to anti-EBNA-1 antibodies, then to lupus-specific autoantibodies, and finally to the inflammatory damage that produces the systemic symptoms of lupus. A high prevalence of these cross-reactive antibodies in lupus patients supports the idea that the anti-EBV immune response is where lupus autoimmunity originates.
Other Autoimmune Conditions
EBV has also been investigated in rheumatoid arthritis and Sjögren’s syndrome. Studies have found elevated levels of EBV DNA in the blood of rheumatoid arthritis patients compared to healthy controls. The relationship with Sjögren’s syndrome, which attacks moisture-producing glands, is still being explored, with some studies finding overlap between RA patients who also develop Sjögren’s and those with high viral loads. The evidence for these conditions is not as definitive as for MS or lupus, but the pattern of EBV involvement across multiple autoimmune diseases suggests a shared underlying mechanism.
Why Most People With Mono Don’t Get Autoimmune Disease
Given that nearly all adults carry EBV, the virus alone clearly isn’t enough to trigger autoimmune disease. Genetics play a significant role. One gene variant in particular, called HLA-DRB1*1501, is one of the strongest known genetic risk factors for MS, tripling the odds on its own. When combined with EBV infection, the risk climbs even higher. Researchers believe this gene variant affects how immune cells present viral material, making it more likely that EBV-infected cells will accidentally trigger an immune response against the body’s own nervous system tissue.
Vitamin D levels also appear to interact with EBV risk. Low vitamin D and high anti-EBNA-1 antibody levels are independent risk factors for MS, but they also influence each other. Vitamin D deficiency is associated with EBV reactivation, while adequate vitamin D helps the immune system keep the virus in check. Vitamin D also reduces inflammation and may counteract some of the inflammatory pathways that EBV activates. This interaction may partly explain why MS is more common in northern latitudes, where sunlight exposure and vitamin D production are lower.
Vaccine Development
Because EBV is now considered a likely prerequisite for MS and a contributor to other autoimmune diseases, preventing infection in the first place has become a major research priority. Moderna is currently running a Phase 1/2 clinical trial of an mRNA-based EBV vaccine (mRNA-1189) in healthy people aged 10 to 30. The trial is testing different doses for safety and immune response. If successful, an EBV vaccine could potentially prevent not only mono but also reduce the incidence of the autoimmune diseases it triggers, along with EBV-associated cancers. No EBV vaccine is currently approved, so this remains a preventive tool for the future rather than one available today.